Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn's Disease and Ulcerative Colitis Article (Web of Science)

cited authors

  • Merza, Nooraldin; Nawras, Yusuf; Saab, Omar; Dahiya, Dushyant Singh; Ahmed, Zohaib; Ranabothu, Meghana; Boujemaa, Safa; Hassan, Mona; Kobeissy, Abdallah; Lilley, Kirthi

publication date

  • December 1, 2023

webpage

published in

category

keywords

  • Adalimumab
  • Crohn's disease
  • Inflammatory bowel disease
  • PRISMA
  • Ulcerative colitis
  • Vedolizumab

start page

  • 289

end page

  • 306

volume

  • 16

issue

  • 6